BCAX

Bicara Therapeutics Inc. Common Stock NASDAQ Listed Sep 13, 2024

Healthcare ·Biotechnology ·US · bicara.com

$23.09

Mkt Cap $1.3B

52w Low $7.80 92.9% of range 52w High $24.25

50d MA $20.52 200d MA $16.40

P/E (TTM) -8.6x

EV/EBITDA -5.3x

P/B 3.0x

Debt/Equity 0.0x

ROE -34.4%

P/FCF -8.6x

RSI (14) —

ATR (14) —

Beta -1.23

50d MA $20.52

200d MA $16.40

Avg Volume 549.5K

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.

CIK (SEC)

2023658

Phone

617-468-4219

116 Huntington Avenue · Boston, MA 02116 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 26, 2026	AMC	-0.72	-0.68	+5.6%	18.92	-1.4%	-2.9%	+0.6%	+5.1%	+8.4%	+13.5%	—
Nov 10, 2025	AMC	-0.55	-0.67	-21.8%	13.93	-0.9%	+5.7%	+7.0%	+2.4%	+6.1%	+8.0%	—
Aug 12, 2025	AMC	-0.54	-0.50	+7.4%	10.47	+1.5%	+8.2%	+9.0%	+11.2%	+9.6%	+9.9%	—
May 13, 2025	AMC	-0.40	-0.68	-70.0%	13.04	+1.2%	+5.1%	+11.0%	+11.0%	+16.6%	+15.3%	—
Mar 27, 2025	AMC	-0.31	-0.39	-25.8%	13.40	-0.1%	+0.0%	-2.8%	-5.5%	-1.0%	-11.7%	—
Nov 12, 2024	AMC	-0.46	-1.60	-247.8%	22.35	+0.0%	-1.6%	-0.4%	-9.8%	-14.1%	-13.6%	—
Sep 13, 2024	AMC	—	-0.27	—	23.41	-4.6%	+8.5%	+15.6%	+9.9%	+5.1%	+9.4%	—
Jun 30, 2024	AMC	—	-0.27	—	—	—	—	—	—	—	—	—
Dec 31, 2023	AMC	—	-0.23	—	—	—	—	—	—	—	—	—
Sep 30, 2023	AMC	—	-0.42	—	—	—	—	—	—	—	—	—
Jun 30, 2023	AMC	—	-0.15	—	—	—	—	—	—	—	—	—
Mar 31, 2023	AMC	—	-0.15	—	—	—	—	—	—	—	—	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 31	Citizens	Maintains	Market Outperform → Market Outperform	—	$19.04	$19.41	+1.9%	+4.5%	+7.7%	+12.8%	+9.5%	+11.8%
Mar 31	Goldman Sachs	Maintains	Neutral → Neutral	—	$19.04	$19.41	+1.9%	+4.5%	+7.7%	+12.8%	+9.5%	+11.8%
Mar 31	HC Wainwright & Co.	Maintains	Buy → Buy	—	$19.04	$19.41	+1.9%	+4.5%	+7.7%	+12.8%	+9.5%	+11.8%
Mar 31	Wedbush	Maintains	Outperform → Outperform	—	$19.04	$19.41	+1.9%	+4.5%	+7.7%	+12.8%	+9.5%	+11.8%
Mar 31	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$19.04	$19.41	+1.9%	+4.5%	+7.7%	+12.8%	+9.5%	+11.8%
Jan 13	Wedbush	Maintains	Outperform → Outperform	—	$17.43	$17.34	-0.5%	+0.6%	+3.4%	-4.2%	-3.9%	-4.1%
Nov 11	Wells Fargo	Maintains	Equal Weight → Equal Weight	—	$13.93	$13.80	-0.9%	+5.7%	+7.0%	+2.4%	+6.1%	+8.0%
Aug 22	HC Wainwright & Co.	Maintains	Buy → Buy	—	$11.63	$11.63	+0.0%	+1.8%	-2.7%	+3.5%	+3.4%	+2.4%
May 23	Wells Fargo	Upgrade	Underweight → Equal Weight	—	$15.66	$11.65	-25.6%	-40.8%	-36.3%	-39.6%	-39.7%	-40.9%
May 16	HC Wainwright & Co.	Maintains	Buy → Buy	—	$14.47	$13.77	-4.8%	+0.0%	+5.1%	+3.9%	+0.8%	+8.2%
Apr 7	HC Wainwright & Co.	Maintains	Buy → Buy	—	$10.57	$10.24	-3.1%	-10.0%	-11.4%	-1.6%	-4.0%	+1.9%
Mar 13	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$13.01	$12.90	-0.8%	+2.6%	-4.5%	+3.8%	-4.4%	-4.7%
Feb 12	Wedbush	Maintains	Outperform → Outperform	—	$13.02	$12.82	-1.5%	+1.5%	+0.8%	+3.5%	+0.5%	+1.1%
Jan 27	HC Wainwright & Co.	Maintains	Buy → Buy	—	$11.61	$12.03	+3.6%	+0.3%	+3.2%	+1.3%	+11.2%	+8.7%

Date	Insider	Title	Type	Shares	Price	Value	Owned After	D1%	D5%
Apr 27, 2026	Raben DavidOff	Chief Medical Officer	Sell	5,500	$22.88	$126K	55,286	-2.92%	+3.42%

Data updated apr 24, 2026 8:50pm · Source: massive.com